Abiopharma

Impact Biomedical Investor News: Rosen Law Firm Encourages Impact Biomedical Inc. Investors to Inquire About Securities Class Action Investigation – IBO

Dormant shares - change in the number of shares

AbbVie Showcases Late‑Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) at SGO 2026

Changes in the companys name and securitys name, effective as of April 14, 2026

Final dividend update for the share in the amount of 495.23319 agorot per share, record date 14.4.26, payment 23.4.26

Register of shareholders, changes and capital status

Register of shareholders, changes and capital status

Change in holdings of interested parties/officers - amendment of report

Self-purchase/sale of securities – BONDS series Yad, BONDS series Tez

Dormant shares - change in the number of shares